ACS Chemical Biology,
Год журнала:
2023,
Номер
18(5), С. 1180 - 1191
Опубликована: Апрель 27, 2023
SARS-CoV-2
viruses
engage
ACE2
as
a
functional
receptor
with
their
spike
protein.
The
S1
domain
of
the
protein
contains
C-terminal
binding
(RBD)
and
an
N-terminal
(NTD).
NTD
other
coronaviruses
includes
glycan
cleft.
However,
for
NTD,
protein–glycan
was
only
observed
weakly
sialic
acids
highly
sensitive
methods.
Amino
acid
changes
in
variants
concern
(VoC)
show
antigenic
pressure,
which
can
be
indication
NTD-mediated
binding.
Trimeric
proteins
SARS-CoV-2,
alpha,
beta,
delta,
omicron
did
not
reveal
capability.
Unexpectedly,
beta
subvariant
strain
(501Y.V2-1)
to
Vero
E6
cells
sialidase
pretreatment.
Glycan
microarray
analyses
identified
putative
9-O-acetylated
ligand,
confirmed
by
catch-and-release
ESI-MS,
STD-NMR
analyses,
graphene-based
electrochemical
sensor.
variant
attained
enhanced
modality
specificity
toward
structures,
suggesting
dual-receptor
functionality
domain,
quickly
selected
against.
These
results
indicate
that
probe
additional
evolutionary
space,
allowing
receptors
on
surface
target
cells.
Cell,
Год журнала:
2022,
Номер
186(2), С. 279 - 286.e8
Опубликована: Дек. 14, 2022
The
BQ
and
XBB
subvariants
of
SARS-CoV-2
Omicron
are
now
rapidly
expanding,
possibly
due
to
altered
antibody
evasion
properties
deriving
from
their
additional
spike
mutations.
Here,
we
report
that
neutralization
BQ.1,
BQ.1.1,
XBB,
XBB.1
by
sera
vaccinees
infected
persons
was
markedly
impaired,
including
individuals
boosted
with
a
WA1/BA.5
bivalent
mRNA
vaccine.
Titers
against
were
lower
13-
81-fold
66-
155-fold,
respectively,
far
beyond
what
had
been
observed
date.
Monoclonal
antibodies
capable
neutralizing
the
original
variant
largely
inactive
these
new
subvariants,
responsible
individual
mutations
identified.
These
found
have
similar
ACE2-binding
affinities
as
predecessors.
Together,
our
findings
indicate
present
serious
threats
current
COVID-19
vaccines,
render
all
authorized
antibodies,
may
gained
dominance
in
population
because
advantage
evading
antibodies.
Abstract
Continuous
evolution
of
Omicron
has
led
to
a
rapid
and
simultaneous
emergence
numerous
variants
that
display
growth
advantages
over
BA.5
(ref.
1
).
Despite
their
divergent
evolutionary
courses,
mutations
on
receptor-binding
domain
(RBD)
converge
several
hotspots.
The
driving
force
destination
such
sudden
convergent
its
effect
humoral
immunity
remain
unclear.
Here
we
demonstrate
these
can
cause
evasion
neutralizing
antibody
drugs
convalescent
plasma,
including
those
from
breakthrough
infection,
while
maintaining
sufficient
ACE2-binding
capability.
BQ.1.1.10
(BQ.1.1
+
Y144del),
BA.4.6.3,
XBB
CH.1.1
are
the
most
antibody-evasive
strains
tested.
To
delineate
origin
evolution,
determined
escape
mutation
profiles
neutralization
activity
monoclonal
antibodies
isolated
individuals
who
had
BA.2
infections
2,3
.
Owing
immune
imprinting,
especially
infection
reduced
diversity
binding
sites
increased
proportions
non-neutralizing
clones,
which,
in
turn,
focused
pressure
promoted
RBD.
Moreover,
show
RBD
could
be
accurately
inferred
by
deep
mutational
scanning
4,5
,
trends
BA.2.75
subvariants
well
foreseen
through
constructed
pseudovirus
mutants.
These
results
suggest
current
herd
vaccine
boosters
may
not
efficiently
prevent
variants.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2022,
Номер
unknown
Опубликована: Сен. 16, 2022
Abstract
Continuous
evolution
of
Omicron
has
led
to
a
rapid
and
simultaneous
emergence
numerous
variants
that
display
growth
advantages
over
BA.
5.
Despite
their
divergent
evolutionary
courses,
mutations
on
receptor-binding
domain
(RBD)
converge
several
hotspots.
The
driving
force
destination
such
convergent
its
impact
humoral
immunity
remain
unclear.
Here,
we
demonstrate
these
can
cause
striking
evasion
neutralizing
antibody
(NAb)
drugs
convalescent
plasma,
including
those
from
BA.5
breakthrough
infection,
while
maintaining
sufficient
ACE2
binding
capability.
BQ.1.1.10,
BA.4.6.3,
XBB,
CH.
1.1
are
the
most
antibody-evasive
strain
tested,
even
exceeding
SARS-CoV-1
level.
To
delineate
origin
evolution,
determined
escape
mutation
profiles
neutralization
activity
monoclonal
antibodies
(mAbs)
isolated
BA.2
breakthrough-infection
convalescents.
Importantly,
due
immune
imprinting,
especially
infection
caused
significant
reductions
in
epitope
diversity
NAbs
increased
proportion
non-neutralizing
mAbs,
which
turn
concentrated
pressure
promoted
evolution.
Moreover,
showed
RBD
could
be
accurately
inferred
by
integrated
deep
mutational
scanning
(DMS)
profiles,
trends
BA.2.75/BA.5
subvariants
well-simulated
through
constructed
pseudovirus
mutants.
Together,
our
results
suggest
current
herd
vaccine
boosters
may
not
provide
good
protection
against
infection.
Broad-spectrum
SARS-CoV-2
vaccines
NAb
development
should
highly
prioritized,
mutants
help
examine
effectiveness
advance.
Cell Host & Microbe,
Год журнала:
2022,
Номер
30(11), С. 1527 - 1539.e5
Опубликована: Окт. 4, 2022
Recently
emerged
SARS-CoV-2
Omicron
subvariant,
BA.2.75,
displayed
a
growth
advantage
over
circulating
BA.2.38,
BA.2.76,
and
BA.5
in
India.
However,
the
underlying
mechanisms
for
enhanced
infectivity,
especially
compared
with
BA.5,
remain
unclear.
Here,
we
show
that
BA.2.75
exhibits
substantially
higher
affinity
host
receptor
angiotensin-converting
enzyme
2
(ACE2)
than
other
variants.
Structural
analyses
of
spike
shows
its
decreased
thermostability
increased
frequency
binding
domain
(RBD)
"up"
conformation
under
acidic
conditions,
suggesting
low-pH-endosomal
cell
entry.
Relative
to
BA.4/BA.5,
reduced
evasion
humoral
immunity
from
BA.1/BA.2
breakthrough-infection
convalescent
plasma
but
greater
Delta
plasma.
also
weaker
neutralization
against
mainly
due
BA.2.75's
distinct
neutralizing
antibody
(NAb)
escape
pattern.
Antibody
therapeutics
Evusheld
Bebtelovimab
effective
BA.2.75.
These
results
suggest
may
prevail
after
receptor-binding
capability
could
support
further
immune-evasive
mutations.
Cell Host & Microbe,
Год журнала:
2022,
Номер
30(11), С. 1512 - 1517.e4
Опубликована: Сен. 6, 2022
The
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
Omicron
subvariant
BA.2.75
emerged
recently
and
appears
to
be
spreading.
It
has
nine
mutations
in
spike
compared
with
the
currently
circulating
BA.2,
raising
concerns
that
it
may
further
evade
vaccine-elicited
therapeutic
antibodies.
We
found
moderately
more
neutralization
resistant
sera
from
vaccinated/boosted
individuals
than
BA.2
(1.8-fold),
similar
BA.2.12.1
(1.1-fold),
but
sensitive
BA.4/5
(0.6-fold).
Relative
showed
heightened
resistance
class
1
3
monoclonal
antibodies
targeting
spike-receptor-binding
domain
while
gaining
sensitivity
Resistance
was
largely
conferred
by
G446S
R460K
mutations.
slightly
(3.7-fold)
bebtelovimab,
a
antibody
potent
activity
against
all
subvariants.
also
exhibited
higher
binding
affinity
host
receptor
ACE2
other
provides
insight
into
SARS-CoV-2
evolution
as
gains
transmissibility
incrementally
evading
neutralization.
Journal of Clinical Investigation,
Год журнала:
2023,
Номер
133(1)
Опубликована: Янв. 2, 2023
Infections
with
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
and
vaccinations
targeting
the
spike
protein
(S)
offer
protective
immunity
against
disease
2019
(COVID-19).
This
may
further
be
shaped
by
cross-reactivity
common
cold
coronaviruses.
Mutations
arising
in
S
that
are
associated
altered
intrinsic
virus
properties
immune
escape
result
continued
circulation
of
SARS-CoV-2
variants.
Potentially,
vaccine
updates
will
required
to
protect
future
variants
concern,
as
for
influenza.
To
potent
protection
variants,
these
second-generation
vaccines
need
redirect
epitopes
not
merely
boost
toward
conserved
domains
preimmune
individuals.
For
influenza,
efficacy
repeated
vaccination
is
hampered
original
antigenic
sin,
an
attribute
memory
leads
greater
induction
antibodies
specific
first-encountered
variant
immunogen
compared
subsequent
In
this
Review,
recent
findings
on
sin
discussed
context
evolution.
Unanswered
questions
directions
highlighted,
emphasis
impact
outcome
design.
Science Immunology,
Год журнала:
2022,
Номер
7(78)
Опубликована: Ноя. 10, 2022
Numerous
safe
and
effective
coronavirus
disease
2019
vaccines
have
been
developed
worldwide
that
use
various
delivery
technologies
engineering
strategies.
We
show
here
containing
prefusion-stabilizing
S
mutations
elicit
antibody
responses
in
humans
with
enhanced
recognition
of
the